Immunogenicity and safety of CoronaVac vaccine (Covid-19 vaccine) in Thai people with underlying disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220720001

Enrollment

420

Registered

2022-07-20

Start date

2021-06-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus Cirrhosis solid cancer Hematologic malignancy chronic kidney disease rheumatological disease cardiovascular disease CoronaVac vaccine immunogenicity covid-19 vaccine

Interventions

CoronaVac vaccine 2 doses 4 weeks apart intramuscular

Experimental Biological/Vaccine

CoronaVac

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. age more than 18 years old 2. Anti-SAR-CoV-2 negative 3. diabetes mellitus or 4. cirrhosis or 5. solid cancer or 6. hematologic malignancy or 7. chronic kidney disease (GFR <60 ml/mi/1.73 m2) 8. rheumatological disease or 9. cardiovascular disease

Exclusion criteria

Exclusion criteria: 1. previous covid-19 vaccination 2. prior other vaccine in 14 days 3. pregnancy 4. lactation

Design outcomes

Primary

Measure	Time frame
The change of geometric mean titer levels to RBD of spike protein compare baseline and 4 weeks after 2nd doses anti-Sar-Cov2	—

Secondary

Measure	Time frame
Immunogenicity response 4 weeks after 2nd doses anti-Sar-Cov2	—

Countries

Thailand

Contacts

Public ContactKriangkrai Tawinprai

Chulabhorn Hospital

kriangkrai.taw@cra.ac.th025766000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026